| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Chieh-Hsin Lin, Kuo-Hao Huang, Yue-Cune Chang, Yi-Chen Huang, Wan-Chih Hsu, Chun-Yuan Lin, Frank Huang-Chih Chou, Guochuan E Tsai, Hsien-Yuan Lan. Clozapine protects bone mineral density in female patients with schizophrenia. The international journal of neuropsychopharmacology. vol 15. issue 7. 2012-12-11. PMID:22014454. |
clozapine protects bone mineral density in female patients with schizophrenia. |
2012-12-11 |
2023-08-12 |
Not clear |
| Eesha Sharma, Naren P Rao, Ganesan Venkatasubramanian, Rishikesh V Behere, Shivarama Varambally, Bangalore N Gangadha. Successful treatment of co-morbid schizophrenia and multiple sclerosis. Asian journal of psychiatry. vol 3. issue 4. 2012-12-10. PMID:23050895. |
we, for the first time, report a patient with ms and paranoid schizophrenia successfully treated with concurrent use of clozapine and risperidone with interferon-beta-1a. |
2012-12-10 |
2023-08-12 |
Not clear |
| Taral R Sharma, Ritu Chahi. Dose dependent, new onset QTc prolongation in a patient with paranoid schizophrenia receiving Clozapine. Asian journal of psychiatry. vol 4. issue 3. 2012-12-10. PMID:23051123. |
dose dependent, new onset qtc prolongation in a patient with paranoid schizophrenia receiving clozapine. |
2012-12-10 |
2023-08-12 |
Not clear |
| Zoja Babinkostova, Branislav Stefanovsk. Forms of antipsychotic therapy: improved individual outcomes under personalised treatment of schizophrenia focused on depression. The EPMA journal. vol 2. issue 4. 2012-12-04. PMID:23199176. |
most of the studies referred that clozapine, olanzapine, quetiapine and risperidone have an antidepressant spectrum of activity in patients with schizophrenia. |
2012-12-04 |
2023-08-12 |
Not clear |
| Nobumi Miyake, Seiya Miyamoto, L Fredrik Jarsko. New serotonin/dopamine antagonists for the treatment of schizophrenia: are we making real progress? Clinical schizophrenia & related psychoses. vol 6. issue 3. 2012-11-29. PMID:23006237. |
the introduction of second-generation antipsychotics (sgas), heralded by clozapine in 1990, represented an important advance in the pharmacologic treatment of schizophrenia. |
2012-11-29 |
2023-08-12 |
Not clear |
| Herbert Y Meltze. Clozapine: balancing safety with superior antipsychotic efficacy. Clinical schizophrenia & related psychoses. vol 6. issue 3. 2012-11-29. PMID:23006238. |
clozapine is often referred to as the gold standard for the treatment of schizophrenia and yet has also been described as the most underutilized treatment for schizophrenia supported by solid evidence-based medicine. |
2012-11-29 |
2023-08-12 |
Not clear |
| Herbert Y Meltze. Clozapine: balancing safety with superior antipsychotic efficacy. Clinical schizophrenia & related psychoses. vol 6. issue 3. 2012-11-29. PMID:23006238. |
in 2008, it was used to treat only 4.4% of patients with schizophrenia in the u.s., which is ~10-20% of those with approved indications for clozapine for which there is no alternative of equal efficacy. |
2012-11-29 |
2023-08-12 |
Not clear |
| Herbert Y Meltze. Clozapine: balancing safety with superior antipsychotic efficacy. Clinical schizophrenia & related psychoses. vol 6. issue 3. 2012-11-29. PMID:23006238. |
the primary indications for clozapine are: 1) treatment-resistant schizophrenia or schizoaffective disorder, defined as persistent moderate to severe delusions or hallucinations despite two or more clinical trials with other antipsychotic drugs; and, 2) patients with schizophrenia or schizoaffective disorder who are at high risk for suicide. |
2012-11-29 |
2023-08-12 |
Not clear |
| Rudi Hwang, Arun K Tiwari, Clement C Zai, Daniel Felsky, Eli Remington, Tessa Wallace, Ryan P Tong, Renan P Souza, Gabriel Oh, Steven G Potkin, Jeffrey A Lieberman, Herbert Y Meltzer, James L Kenned. Dopamine D4 and D5 receptor gene variant effects on clozapine response in schizophrenia: replication and exploration. Progress in neuro-psychopharmacology & biological psychiatry. vol 37. issue 1. 2012-11-08. PMID:22203087. |
dopamine d4 and d5 receptor gene variant effects on clozapine response in schizophrenia: replication and exploration. |
2012-11-08 |
2023-08-12 |
Not clear |
| Azizah Attard, David M Taylo. Comparative effectiveness of atypical antipsychotics in schizophrenia: what have real-world trials taught us? CNS drugs. vol 26. issue 6. 2012-10-29. PMID:22668246. |
the catie (clinical antipsychotic trials of intervention effectiveness), cutlass (cost utility of the latest antipsychotic drugs in schizophrenia study) and soho (schizophrenia outpatient health outcomes) programmes confirmed the superiority of clozapine over other antipsychotics; catie and soho also confirmed olanzapine as probably the second most effective antipsychotic. |
2012-10-29 |
2023-08-12 |
Not clear |
| James I Wasserman, Rebecca J Barry, Lisa Bradford, Nicholas J Delva, Richard J Beninge. Probabilistic classification and gambling in patients with schizophrenia receiving medication: comparison of risperidone, olanzapine, clozapine and typical antipsychotics. Psychopharmacology. vol 222. issue 1. 2012-10-22. PMID:22237855. |
probabilistic classification and gambling in patients with schizophrenia receiving medication: comparison of risperidone, olanzapine, clozapine and typical antipsychotics. |
2012-10-22 |
2023-08-12 |
Not clear |
| Domenico De Berardis, Nicola Serroni, Daniela Campanella, Luigi Olivieri, Francesca Ferri, Alessandro Carano, Marilde Cavuto, Giovanni Martinotti, Alessandra Cicconetti, Monica Piersanti, Francesco Saverio Moschetta, Massimo Di Giannantoni. Update on the adverse effects of clozapine: focus on myocarditis. Current drug safety. vol 7. issue 1. 2012-10-22. PMID:22663959. |
moreover, clozapine appears to be particularly beneficial in patients with schizophrenia who are suicidal and in those with comorbid substance use disorder. |
2012-10-22 |
2023-08-12 |
Not clear |
| Jaromir Hons, Martina Vasatova, Eva Cermakova, Pavel Doubek, Jan Libige. Different serine and glycine metabolism in patients with schizophrenia receiving clozapine. Journal of psychiatric research. vol 46. issue 6. 2012-10-17. PMID:22502820. |
different serine and glycine metabolism in patients with schizophrenia receiving clozapine. |
2012-10-17 |
2023-08-12 |
Not clear |
| Jaromir Hons, Martina Vasatova, Eva Cermakova, Pavel Doubek, Jan Libige. Different serine and glycine metabolism in patients with schizophrenia receiving clozapine. Journal of psychiatric research. vol 46. issue 6. 2012-10-17. PMID:22502820. |
to examine eaa serum levels in relation to the intensity of psychotic symptoms and the type of medication received we compared these variables among patients with schizophrenia (n = 49) treated with first (fga) or second (sga) generation antipsychotics or clozapine. |
2012-10-17 |
2023-08-12 |
Not clear |
| N B Pai, M Laidlaw, S-C Vell. Augmentation of clozapine with another pharmacological agent: treatment for refractory schizophrenia in the 'real world'. Acta psychiatrica Scandinavica. vol 126. issue 1. 2012-10-03. PMID:22432694. |
augmentation of clozapine with another pharmacological agent: treatment for refractory schizophrenia in the 'real world'. |
2012-10-03 |
2023-08-12 |
Not clear |
| S Pallanti, L Quercioli, A Pazzagl. Social anxiety and premorbid personality disorders in paranoid schizophrenic patients treated with clozapine. CNS spectrums. vol 5. issue 9. 2012-10-02. PMID:17637578. |
in this paper, 12 cases of patients with paranoid schizophrenia who developed social phobia during clozapine treatment are reported, and their response to fluoxetine augmentation is assessed. |
2012-10-02 |
2023-08-12 |
Not clear |
| S Pallanti, L Quercioli, A Pazzagl. Social anxiety and premorbid personality disorders in paranoid schizophrenic patients treated with clozapine. CNS spectrums. vol 5. issue 9. 2012-10-02. PMID:17637578. |
furthermore, in 7 (58.3%) of the 12 cases, an anxious personality disorder (avoidant=33.3%; dependent=25%) was identified, but no significant differences in the prevalence of comorbid personality disorders emerged in comparison with a group of 16 patients with paranoid schizophrenia treated with clozapine who did not show symptoms of social phobia. |
2012-10-02 |
2023-08-12 |
Not clear |
| S Pallanti, L Quercioli, A Pazzagl. Social anxiety and premorbid personality disorders in paranoid schizophrenic patients treated with clozapine. CNS spectrums. vol 5. issue 9. 2012-10-02. PMID:17637578. |
considering that the onset of anxiety-spectrum disorders (such as social phobia) can occur during the remission of psychotic symptoms in clozapine-treated patients with schizophrenia, a comprehensive approach to pharmacological therapy for patients with schizophrenia (or, at least for those treated with clozapine) should be adopted. |
2012-10-02 |
2023-08-12 |
Not clear |
| S Morris, T Hogan, A McGuir. The cost-effectiveness of clozapine: a survey of the literature. Clinical drug investigation. vol 15. issue 2. 2012-10-02. PMID:18370477. |
a review of published cost-effectiveness studies of clozapine conducted in the usa, uk, sweden and canada, and employing a variety of study designs, reveals consistent reporting of clinical efficacy, cost and cost-effectiveness findings in favour of clozapine over conventional antipsychotics in the management of treatment-resistant schizophrenia. |
2012-10-02 |
2023-08-12 |
Not clear |
| S Morris, T Hogan, A McGuir. The cost-effectiveness of clozapine: a survey of the literature. Clinical drug investigation. vol 15. issue 2. 2012-10-02. PMID:18370477. |
all reported economic evidence indicates that, despite its higher acquisition cost, clozapine nevertheless represents cost-effective therapy for treatment-resistant schizophrenia. |
2012-10-02 |
2023-08-12 |
Not clear |